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Abstract
The cytoplasmic peptide:N-glycanase (Ngly1 in mammals) is a de-N-glycosylating enzyme
that is highly conserved among eukaryotes. It was recently reported that subjects harboring
mutations in the NGLY1 gene exhibited severe systemic symptoms (NGLY1-deficiency).
While the enzyme obviously has a critical role in mammals, its precise function remains
unclear. In this study, we analyzed Ngly1-deficient mice and found that they are embryonic
lethal in C57BL/6 background. Surprisingly, the additional deletion of the gene encoding
endo-β-N-acetylglucosaminidase (Engase), which is another de-N-glycosylating enzyme
but leaves a single GlcNAc at glycosylated Asn residues, resulted in the partial rescue of the
lethality of the Ngly1-deficient mice. Additionally, we also found that a change in the genetic
background of C57BL/6 mice, produced by crossing the mice with an outbred mouse strain
(ICR) could partially rescue the embryonic lethality of Ngly1-deficient mice. Viable Ngly1-
deficient mice in a C57BL/6 and ICR mixed background, however, showed a very severe
phenotype reminiscent of the symptoms of NGLY1-deficiency subjects. Again, many of
those defects were strongly suppressed by the additional deletion of Engase in the C57BL/6
and ICR mixed background. The defects observed in Ngly1/Engase-deficient mice (C57BL/
6 background) and Ngly1-deficient mice (C57BL/6 and ICR mixed background) closely
resembled some of the symptoms of patients with an NGLY1-deficiency. These observa-
tions strongly suggest that the Ngly1- or Ngly1/Engase-deficient mice could serve as a valu-
able animal model for studies related to the pathogenesis of the NGLY1-deficiency, and that
cytoplasmic ENGase represents one of the potential therapeutic targets for this genetic
disorder.
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Author summary
Ngly1 is a cytoplasmic de-N-glycosylating enzyme that is ubiquitously found in eukary-
otes. This enzyme is involved in a process referred to as endoplasmic reticulum-associated
degradation (ERAD), one of the quality control mechanisms for newly synthesized pro-
teins. A genetic disorder, NGLY1-deficiency, caused by mutations in the NGLY1 gene has
recently been discovered. However, the precise mechanism for the pathogenesis of this
devastating disease continues to remain unclear. We report herein that Ngly1-deficient
mice are embryonically lethal in a C57BL/6 background. Surprisingly, the lethality was
suppressed by crossing the mice with an outbred mouse strain (ICR), suggesting that the
phenotypic consequence of Ngly1 is greatly influenced by their genetic background. In
both cases, the additional deletion of Engase in Ngly1-deficient mice could strongly miti-
gate the phenotypes. Interestingly, the remaining defects in Ngly1-deficient or Ngly1/
Engase-deficient mice were reminiscent of the symptoms of subjects with an NGLY1-defi-
ciency. Our results clearly point to the importance of Ngly1 in mammals and show that
the inhibition of ENGase represents an effective therapy for treating an NGLY1-defi-
ciency. Most importantly, the mice described herein could serve as valuable viable model
mice for studies related to the pathophysiology of an NGLY1-deficiency.
Introduction
The endoplasmic reticulum (ER) is the organelle responsible for the biosynthesis of proteins
that pass through the secretory pathway. This organelle has an efficient protein quality control
or homeostasis system, in which abnormal or excess proteins are targeted for destruction [1–
3]. In such systems, cytoplasmic proteasomes play a major role in degrading proteins, and the
degradation system is often referred to as ER-associated degradation, or ERAD in short. Ngly1
is a highly conserved deglycosylating enzyme that is involved in the ERAD process [4–6].
Ngly1 cleaves N-glycans from misfolded glycoproteins during the ERAD process, and is
thought to play an important role in the efficient degradation of misfolded glycoproteins [7–
11]. N-glycans released by Ngly1 are known to be processed by cytoplasmic glycosidases such
as ENGase and the α-mannosidase, Man2C1 (Fig 1A, upper scheme) [12–14]. Cytoplasmic
ENGase is another deglycosylating enzyme that acts directly on N-glycans that are attached to
glycoproteins but leaves a single N-acetylglucosamine (GlcNAc) residue attached to the pro-
tein (Fig 1A, lower scheme). This enzyme belongs to the Glycosyl Hydrolase (GH) family 85,
and while conserved widely in eukaryotes, some yeast, including S. cerevisiae and S. pombe, do
not produce this enzyme.
Several studies dealing with the biological functions of Ngly1 and/or ENGase have been
reported. Mutants of Ngly1 and its orthologues have been analyzed in various organisms [7,
15–19]. Interestingly, the phenotypic consequences were found to be quite distinct between
species; for example, budding yeast show no significant viability/growth defects [7], while
mutant flies exhibited severe growth delay/arrest [15]. The molecular details behind the phe-
notypes, however, remain poorly understood. As of this writing, mutants of Engase have been
analyzed in A. thaliana [20] and C. elegans [21] but, in both cases, no significant phenotypes
were observed.
In 2012, the first patient harboring mutations in NGLY1 alleles (NGLY1-deficiency) was
identified through an exome analysis [22] and, since then, clinical cases involving humans
have been reported [23–26]. These patients show very severe systemic symptoms such as
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delayed global development, movement disorders, hypotonia and hypo/alacrima [24, 26].
These reports point to the biological significance of Ngly1 in the normal development of mam-
mals. More recently, using a model ERAD substrate, we reported that the ablation of Ngly1
causes a disruption in the ERAD process in mouse embryonic fibroblast (MEF) cells [27].
Interestingly, this ERAD disruption was found to be caused by an unexpected deglycosylating
activity of ENGase, and the direct action of this enzyme towards the model substrate was
shown to result in the formation of aggregation-prone N-GlcNAc proteins [27]. Moreover, the
disruption of ERAD in Ngly1-deficient cells was restored by the additional deletion of the
Engase gene. While this result using a model substrate suggests that an ENGase inhibitor could
be a potential therapeutic target for treating an NGLY1-deficiency, the issue of how Engase-
deletion affects mice phenotypes lacking Ngly1 remains unknown.
Fig 1. Generation of Ngly1- and Engase-deficient mice. (A) Schematic views of the non-lysosomal degradation of free oligosaccharides (upper
scheme) and the action of ENGase on glycoproteins (lower scheme). (B, C) A diagram of the targeting construct used to generate Ngly1-deficient mice
(B) and Engase-deficient mice (C) (Figures Reproduced from ref. 27). In the Ngly1−/− allele, from exon 11 to 12 were flanked by loxP site (filled
triangles). Open triangles indicate FRT sites. In Engase−/− allele, exon 5 was replaced with a PGK-Neor cassette. (D) Cytoplasmic fraction of MEF cells
derived from Ngly1−/− or Ngly1+/+ (wild type, WT) embryos were immunoblotted with an antibody against mouse Ngly1. GAPDH was used as a loading
control. Allow indicates Ngly1 and asterisks indicate non-specific bands.
https://doi.org/10.1371/journal.pgen.1006696.g001
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Results
Ngly1−/− mice in C57BL/6 are embryonically lethal
The goal of this study was to clarify the details of the biological function of the deglycosylating
enzymes, Ngly1 and ENGase, at the individual level in mice. To this end, we used mice
(C57BL/6 background mice) that had been generated in a previous study, in which the Ngly1
and Engase genes had been knocked out [27]. The knockout constructs of Ngly1 and Engase
are shown in Fig 1B and 1C, respectively. While the generation of these KO mice has been
described previously [27], a detailed phenotypic analysis of those mice has not been reported.
The targeted genomic disruption of Ngly1 and ENGase was confirmed by PCR using 8 sets of
primers (Fig 1B and 1C; S1 Table for primer sequences). The loss of Ngly1 activity was con-
firmed by an activity assay [27]. We further examined the expression of the Ngly1 protein by
western blot analysis using cytoplasmic fractions from MEF cells. As shown in Fig 1D, the loss
of Ngly1 in MEF cells from Ngly1−/− mice was confirmed. In the case of ENGase, we confirmed
the loss of the ENGase activity through an activity assay in a previous study [27] as well as by
conducting a detailed structural analysis of the free oligosaccharides (fOSs) in the cytoplasm of
MEF cells [28]. The Ngly1 heterozygous (Ngly1−/+) mice were fertile and did not show any
obviously recognizable phenotypes. However, viable homozygous Ngly1−/− pups were not pro-
duced, despite the repeated crossing of the Ngly1−/+ mice (Table 1), suggesting that the deletion
of the Ngly1 allele results in a lethal condition in C57BL/6 mice. To delineate the timing of the
Table 1. Results of the genotyping of pups/embryos by crossing of Ngly1−/+, or Ngly1−/+;Engase−/− mice in the C57BL/6 background.
Stage Genotype Number of viable embryos/pups Number of inviable embryos/pups
E14.5 Ngly1+/+ 18 (21.95) [25.00] 0
Ngly1−/+ 50 (60.98) [50.00] 0
Ngly1−/− 14 (17.07) [25.00] 0
E16.5 Ngly1+/+ 56 (28.00) [25.00] 0
Ngly1−/+ 113 (56.50) [50.00] 0
Ngly1−/− 31 (15.50) [25.00] 0
Ngly1+/+;Engase−/− 20 (22.73) [25.00] 0
Ngly1−/+;Engase−/− 52 (59.09) [50.00] 0
Ngly1−/−;Engase−/− 16 (18.18) [25.00] 0
E17.5 Ngly1+/+ 21 (28.77) [25.00] 0
Ngly1−/+ 38 (52.05) [50.00] 1
Ngly1−/− 14 (19.18) [25.00] 7
E18.5 Ngly1+/+ 23 (31.08) [25.00] 0
Ngly1−/+ 38 (51.35) [50.00] 1
Ngly1−/− 13 (17.57) [25.00] 5
P0 Ngly1+/+ 22 −
Ngly1−/+ 35 −
Ngly1−/− 0 −
2 wks Ngly1+/+ 49 −
Ngly1−/+ 84 −
Ngly1−/− 0 −
E: Embryonic day, P: Postnatal day, wks: weeks, V: Viable, IV: Inviable.
(number): birth rates (%), [number]: expected (%).
https://doi.org/10.1371/journal.pgen.1006696.t001
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lethality, Ngly1−/+ mice were crossed and embryos were collected at several stages of gestation.
The viability of collected embryos was confirmed by checking their heart beat and their geno-
types were analyzed using genomic DNA extracted from the amnion. The results of this geno-
typing are summarized in Table 1. The Ngly1−/− embryos were viable, even at embryonic day
18.5 (E18.5), one day prior to birth. At the same time, however, about 30% of Ngly1−/− embryos
were inviable at later stages of development (E17.5–18.5). When embryos were collected early
in the morning of the day of birth, only the Ngly1−/+ and Ngly1+/+ embryos were alive when we
revived them by gentle massaging, but no Ngly1−/− mice could be revived. We also analyzed
the genotype of pups within a few hours after their birth (P0) and confirmed the absence of
Ngly1−/− pups (Table 1). At E14.5 and E16.5, however, only viable Ngly1−/− embryos were
observed. Therefore, the lethality caused by the Ngly1 deficiency appears to occur between
E16.5 and before birth.
A ventricular septal defect is observed in Ngly1−/− embryos
To investigate the defects in Ngly1−/− embryos in more detail, X-ray micro-computed tomogra-
phy (μ-CT) analyses were carried out on Ngly1−/− or Ngly1+/+ embryos at E16.5 (Fig 2A and
2B). As shown in Fig 2B, the Ngly1−/− embryos showed a ventricular septal defect (VSD) (5 out
of 5 embryos (5/5)). Histological analyses also confirmed the occurrence of a VSD in Ngly1−/−
embryos (3/3) (Fig 2C and 2D). VSD is one of the most frequently-observed cardiovascular phe-
notypes in embryonic/perinatal lethal mice [29]. We also found that some Ngly1−/− embryos
showed anemia (12/28 [42.86%], Fig 2E, left panel) or edema (4/28 [14.29%], Fig 2F, left panel),
which were not observed in Ngly1+/+ embryos (0/44, Fig 2E and 2F, right panel).
The additional deletion of the Engase gene partially rescues the lethality
caused by the loss of Ngly1
In sharp contrast to the case of Ngly1−/− mice, the Engase−/− mice showed normal behavior/val-
ues in several tests as follows: behavior test (open field), morphology/behavioral/sensory test
(RIKEN modified-SHIRPA), hematology/clinical chemistry test (hematology, urinalysis, clini-
cal blood chemistry), pathology test (body weight), cardiovascular test (blood pressure, electro-
cardiogram) and neurology/psychiatry test (light/dark transition, home-cage activity, tail
suspension, hot plate, tail flick) (the number of tested mice are described in Materials and
Methods). According to our previous cell-based study using an ERAD model substrate [27],
we hypothesized that ENGase could have the ability to function as a deglycosylating enzyme
and that its deletion could rescue the defects caused by the lack of Ngly1. In this study, we
attempted to verify the effect of the additional Engase deletion of Ngly1−/− in mice at an indi-
vidual level. To this end, we crossed Ngly1−/+;Engase−/+ or Ngly1−/+;Engase−/− mice and found
that surviving Ngly1−/− mice were produced upon the crossing (Table 2). Upon further exami-
nation, all of the surviving mice were found to be Ngly1−/−;Engase−/− double-knockout mice,
strongly indicating that the additional deletion of Engase partially rescued the lethality caused
by the defect of Ngly1 at an individual level.
VSD appears to be one of the critical causes of lethality in Ngly1−/− mice
We next investigated the issue of whether VSD was present in Ngly1−/−;Engase−/− embryos at
E16.5. If VSD was to be critical for the lethality of Ngly1−/− embryos, then this phenotype
should be suppressed by the additional deletion of Engase. As we expected, VSD was not
observed in the Ngly1−/−;Engase−/− embryos, as evidenced by μ-CT (0/2) and histological anal-
yses (0/2) (Fig 2G and 2H). It is therefore possible that VSD is at least one of the critical pheno-
types that cause the lethality of Ngly1−/− mice/embryos and the deletion of the Engase gene, for
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unknown reasons, rescues this phenotype. We also examined the gross morphology of
embryos at E16.5 and found that some Ngly1−/−;Engase−/− embryos showed anemia (5/16
[31.25%], Fig 2I, left panel) while no Ngly1+/+;Engase−/− embryo showed this phenotype (0/20,
Fig 2I, right panel). Additionally, Ngly1−/−;Engase−/− embryos did not show edema (0/16).
Unexpectedly, there is no significant difference of the appearance ratio between Ngly1−/−
embryos and Ngly1−/−;Engase−/− embryos at E16.5 (Table 1). These results suggest that Engase
Fig 2. Loss of Ngly1 causes ventricular septal defects (VSD) and the additional Engase deletion rescues the VSD phenotypes. (A, B, G)
Maximum intensity projection of heart μ-CT images of E16.5 embryo of wild-type (A), Ngly1−/− (B), and Ngly1−/−;Engase−/− (G). White arrows in (B)
indicates VSD. (C, D, H) Transverse section of wild-type (C), Ngly1−/− (D), and Ngly1−/−;Engase−/− embryo (H) at E16.5 were stained with H&E. White
arrows in (D) indicate VSD. Shown are representative sections (n = 3). Scale bar in (C), (D) and (H) indicate 200 μm. RA: right atrium, RV: right
ventricle, LA: left atrium, LV: left ventricle. (E) Anemia was observed in Ngly1−/− embryo at E16.5 (left panel). Right panel shows Ngly1+/+ embryo at
E16.5 (littermate of the left panel). (F) Edema was observed in Ngly1−/− embryo at E16.5 (left panel). Right panel shows Ngly1+/+ embryo at E16.5
(littermate of the left panel). Black arrowhead indicates edema. (I) Anemia was observed in Ngly1−/−;Engase−/− embryo at E16.5 (left panel). Right
panel shows Ngly1+/+;Engase−/− embryo at E16.5 (littermate of the left panel). Representative images were shown.
https://doi.org/10.1371/journal.pgen.1006696.g002
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deletion resulted in the rescue of not all but several phenotypes caused by Ngly1 deletion such
as VSD and edema. These results also indicated that multiple pathways appear to be involved
in the pathophysiology of Ngly1−/− mice.
Ngly1−/−;Engase−/− mice can survive but they still show several
progressive defects similar to the symptoms of human subjects with an
NGLY1-deficiency
We next analyzed the phenotypes of the viable Ngly1−/−;Engase−/− mice in C57BL/6 back-
ground. When the mice were tested for viability, an apparent decrease in the viability of the
Ngly1−/−;Engase−/− mice was observed after 45 weeks (about 10 months), suggesting that they
show age-related defects (Fig 3A). We then attempted to characterize the major defects that
were observed in Ngly1−/−;Engase−/− mice. When they were young (about 4~5 weeks of age),
the differences between the Ngly1−/−;Engase−/− mice and their littermates were negligible.
However, when they became older (about 6~7 months of age), the Ngly1−/−;Engase−/− mice
showed several defects/abnormal behavior, such as bent spines (Fig 3B, upper panel, 15/15),
trembling (S1 and S2 Movies, 15/15), hind-limb clasping (Fig 3C, S3 Movie, 15/15), and front-
limb shaking (S3 Movie, 15/15). Moreover, the Ngly1−/−;Engase−/− mice showed a significant
reduction in body weight compared to their littermates (Fig 3D and 3E). We currently have no
explanation for why only male Ngly1−/+;Engase−/− mice show a slow weight gain relative to
Ngly1+/+;Engase−/− mice, but it may, in part, be due to the fact that male mice are larger than
female mice and therefore make a change in weight gain could be detected more easily. We
observed no other haploinsufficient effects in male/female Ngly1−/+;Engase−/− mice.
Ngly1−/−;Engase−/− mice also had coarse fur (12/15 [80%]) which may be due to either in-
trinsic skin problems or, alternatively, impaired grooming behavior (Fig 3F). Female Ngly1−/−;
Table 2. Genotyping results of pups by crossing of Ngly1−/+;Engase−/+ mice or Ngly1−/+;Engase−/−
mice in C57BL/6 background.
Ngly1−/+;Engase−/+ × Ngly1−/+;Engase−/+
Genotype Number of pups (%) Expected %
Ngly1+/+;Engase−/− 11 (9.40) 6.25
Ngly1−/+;Engase−/− 20 (17.09) 12.50
Ngly1−/−;Engase−/− 3 (2.56)* 6.25
Ngly1+/+;Engase+/− 20 (17.09) 12.50
Ngly1−/+;Engase+/− 34 (29.06) 25.00
Ngly1−/−;Engase+/− 0 (0.00)*** 12.50
Ngly1+/+;Engase+/+ 8 (6.84) 6.25
Ngly1−/+;Engase+/+ 21 (17.95) 12.50
Ngly1−/−;Engase+/+ 0 (0.00)*** 6.25
Ngly1−/+;Engase−/− × Ngly1−/+;Engase−/−
Genotype Number of pups (%) Expected %
Ngly1+/+;Engase−/− 73 (28.52) 25.00
Ngly1−/+;Engase−/− 160 (62.5)*** 50.00
Ngly1−/−;Engase−/− 23 (8.98)*** 25.00
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Engase−/− mice exhibited eye opacity much more frequently than their littermates after 20~30
weeks of age (8/10 [80%], Fig 3G). Those results clearly indicate that, while the deletion of the
Fig 3. Ngly1−/−;Engase−/− mice survive but still show several defects (A) Survival curve of Ngly1−/−;Engase−/− male mice (n = 8), Ngly1−/+;Engase−/−
male mice (n = 16), and Ngly1+/+;Engase−/− male mice (n = 7) in the C57BL/6 background. (B) Macroscopic comparison of 10 months-old Ngly1−/−;
Engase−/− mice (upper panel) and Ngly1+/+;Engase−/− mice (lower panel). White arrow indicates a bent spine. (C) Hind-limb clasping of 5 months-old
Ngly1−/−;Engase−/− mice. White arrowhead indicates clasped hind-limb. (D, E) Change of body weight of Ngly1−/−;Engase−/− mice, Ngly1−/+;Engase−/−
mice, and Ngly1+/+;Engase−/− mice in the C57BL/6 background. (D) shows the results of male mice (n = 3~5) and (E) shows the results of female mice
(n = 3~5). For statistical analysis, Student’s t-test was used. ***:p<0.001, **:p<0.01 (F) Ngly1−/−;Engase−/− mice developed coarse fur (n = 12). (G)
Female Ngly1−/−;Engase−/− mice developed eye opacity (n = 8). Shown are representative appearances.
https://doi.org/10.1371/journal.pgen.1006696.g003
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Engase gene results in suppressing the critical phenotypes, including the VSD caused by deletion
of the Ngly1 gene, not all of the defects were fully rescued.
A change in the genetic background of C57BL/6 mice can partially
rescue the embryonic lethality caused by the loss of Ngly1
It was previously shown that a change in the genetic background of Fut8−/− mice from an
inbred C57BL/6 strain to an outbred ICR strain, that maintain a certain genetic variation
within the colonies, postnatal lethality was rescued [30]. It is also noteworthy that, when we
examined the symptoms of NGLY1-deficiency patients, there were a wide spectrum of symp-
toms and a genotype-phenotype correlation was not so obvious [23–25]. These results imply
that the genetic background may influence the severity of the phenotypes caused by the defects
of Ngly1. With that in mind, we crossed Ngly1−/+ mice in a C57BL/6 background with ICR
mice. Among the F1 mice that were produced, the Ngly1−/+ mice were further crossed to pro-
duce F2 mice. As shown in Table 3, we found that viable F2 Ngly1−/− mice were obtained from
these crosses. The phenotypes of the Ngly1−/− mice in the C57BL/6 and ICR mixed background
were found to be much more severe compared with the Ngly1−/−;Engase−/− mice in the C57BL/
6 background, and about 70% of them died within 3 weeks (Fig 4A). The Ngly1−/− mice in the
C57BL/6 and ICR mixed background also showed a significant reduction in body weight (Fig
4B and 4C) and hind-limb clasping (Fig 4D, 9/9), which were also observed in aged Ngly1−/−;
Engase−/− mice in the C57BL/6 background (Fig 3C–3E). It should be noted that the deletion
of the Engase gene resulted in a slight reduction in the body weight in mice of the C57BL/6
and ICR mixed background (ex. compare Fig 3B, 3C, 3D and 3E for Ngly1−/+ mice). This
observation suggests that the loss of the Engase gene affects weight gain in mice. We suspect,
however, that this fluctuation in the data could be simply due to the diverse genetic back-
ground of the mice that were analyzed, especially since ICR mice are, in general, much larger
than C57BL/6 mice. Consistent with this assumption, pathological tests at the Japan mice clinic
showed that the average weight of 26-week old Engase−/− mice (average 26.64/26.61 g for male/
female mice (n = 5)) was not affected when compared with that of wild-type mice (26.79/26.64
g for male/female mice (n = 1)) with the C57BL/6 background. However, we currently cannot
Table 3. Genotyping results of pups by the crossing of Ngly1−/+ mice or Ngly1−/+;Engase−/− mice in
C57BL/6 and ICR mixed background.
Ngly1−/+ × Ngly1−/+
Genotype Number of pups (%) Expected %
Ngly1+/+ 60 (30.46) 25.00
Ngly1−/+ 106 (53.81) 50.00
Ngly1−/− 31 (15.73)*** 25.00
Ngly1−/+;Engase−/− ×Ngly1−/+;Engase−/−
Genotype Number of pups (%) Expected %
Ngly1+/+;Engase−/− 20 (27.40) 25.00
Ngly1−/+;Engase−/− 44 (60.27) 50.00
Ngly1−/−;Engase−/− 9 (12.33)* 25.00
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exclude the possibility that the loss of the Engase gene may become problematic when Ngly1
levels are compromised.
Fig 4. Engase-deletion improves the % survival and partially rescues the body weight loss of viable Ngly1−/− mice. (A) Survival curve for Ngly1−/−;
Engase−/− mice (n = 9) and Ngly1−/− mice (n = 29) in the C57BL/6 and ICR mixed background. (B, C) Change of body weight of Ngly1−/+ mice and Ngly1−/−
mice in C57BL/6 and ICR mixed background. (B) shows the results of male mice (Ngly1−/+:n = 3~4, Ngly1−/−:n = 2~5) and (C) shows the results of female
mice (Ngly1−/+:n = 5~11, Ngly1−/−:n = 2~5). (D) Hind-limb clasping of 4 weeks-old Ngly1−/− mice in the C57BL/6 and ICR mixed background. (E, F) Change
in body weight of Ngly1−/+;Engase−/− mice and Ngly1−/−;Engase−/− mice in the C57BL/6 and ICR mixed background. (E) shows the results of male mice
(Ngly1−/+;Engase−/−:n = 4~8, Ngly1−/−;Engase−/−:n = 2~4) and (F) shows the results of female mice (Ngly1−/+;Engase−/−:n = 7~11, Ngly1−/−;Engase−/−:
n = 2~3). For statistical analysis, Student’s t-test was used. ***:p<0.001. The number in panel B, C, E, and F indicates the relative ratio of weight of Ngly1−/−
mice to Ngly1−/+ mice at 20 weeks of age.
https://doi.org/10.1371/journal.pgen.1006696.g004
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In the case of the Ngly1−/− mice in the C57BL/6 and ICR mixed background, however, they
began to show these abnormalities when they were still young (4 weeks old). Therefore, the
phenotype of the Ngly1−/− mice in the C57BL/6 and ICR mixed background turned out to be
much more severe than that of Ngly1−/−;Engase−/− mice in the C57BL/6 background, even
when they partially evaded embryonic lethality. These results also indicate the suppressive
effects of the deletion of Engase for phenotypes of Ngly1−/− mice, since mice with the C57BL/6
and ICR mixed background are generally thought to be more tolerant to genetic mutations
when compared with the inbred C57BL/6 background.
To determine if the partial suppression of lethality in the ICR and C57BL/6 mixed back-
ground may have been caused by the low ENGase activity in ICR mice, we carried out ENGase
enzyme assays using PA-labeled sugar derivatives on liver tissue obtained from ICR and C57BL/
6 mice. The findings indicated that the samples from the ICR and C57BL/6 mice had equivalent
ENGase activity (0.39±0.11 pmol/min/mg protein for C57BL/6 and 0.42±0.07pmol/min/mg pro-
tein for ICR), and no ENGase activity was detected in the liver of Engase−/− mouse. These results
indicate that the rescue of the lethality of Ngly1−/− mice resulting from a change in their genetic
background does not appear to be correlated with ENGase activity.
The deletion of Engase can partially alleviate the defects caused by
Ngly1 deletion in viable Ngly1−/− mice
To test the effect of Engase deletion in the viable Ngly1−/− mice, we next generated Ngly1−/−;
Engase−/− mice in the C57BL/6 and ICR mixed background. As shown in Table 3, we were able
to obtain Ngly1−/−;Engase−/− mice in the F3 mice by crossing the F2 Ngly1−/+;Engase−/− mice in
the C57BL/6 and ICR mixed background. All of the F3 Ngly1−/−;Engase−/− mice were alive at 30
weeks (n = 9), in sharp contrast to the case with the F2 Ngly1−/− mice in the C57BL/6 and ICR
mixed background, where none of them had survived at 30 weeks (n = 29) (Fig 4A). Moreover,
the Ngly1−/−;Engase−/− mice showed an attenuated body weight reduction compared to the
Ngly1−/− mice in the C57BL/6 and ICR mixed background (Fig 4E and 4F). These results clearly
indicate that the disruption of ENGase can alleviate, at least partially, the defects caused by Ngly1
deletion in the viable mice (e.g. reduction of % survival and body weight). The phenotypes of the
Ngly1−/−;Engase−/− mice from this cross were found to be even more mild than the Ngly1−/−;
Engase−/− mice in the C57BL/6 background, in that they did not show any overt defects, other
than hind-limb clasping (9/9), suggesting that the deletion of the Engase gene and mixing with
ICR-background have an additive effect in suppressing the defect of the Ngly1−/− mice.
Identification of N-glycoproteins accumulated in the cytoplasm of Ngly1−/−;
Engase−/− and wild-type MEF cells
Regarding the potential mechanism for how ENGase can rescue the defects due to the loss of
Ngly1, we previously proposed an “N-GlcNAc hypothesis” [27]. In this proposed process, ENGase
acts on cytoplasmic misfolded glycoproteins in a stochastic fashion, especially when Ngly1 activity
is compromised. As a result, N-GlcNAc modified proteins (proteins that are modified with one
GlcNAc unit) would be generated in the cytoplasm. The formation of the excessive levels of N-
GlcNAc proteins could somehow lead to detrimental effects (Fig 5A). We also previously showed
that there appears to be higher levels of cytoplasmic N-glycoproteins in Ngly1−/−;Engase−/− MEF
cells compared with wild-type MEF cells, as judged by lectin blot experiments [27]. Such cyto-
plasmic N-glycoproteins may serve as precursors for endogenous N-GlcNAc proteins, some of
which may be linked to the pathogenesis of an NGLY1-deficiency, in Ngly1−/− cells.
To identify specific N-glycoproteins that accumulate in Ngly1−/−;Engase−/− MEF cells, a gly-
coproteomics analysis was carried out on the cytoplasm of Ngly1−/−;Engase−/− MEF cells. To
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minimize contamination from the membrane fraction, we utilized a mild digitonin-treatment
to recover the cytoplasmic fraction [31]. The cytoplasmic fractions thus prepared were sub-
jected to a glycoproteomics analysis. After trypsinization, the N-glycopeptides were concen-
trated by acetone precipitation [32], and the N-glycans were released by PNGase F digestion,
followed by the detection of deglycosylated peptide in which N-glycosylated asparagines are
converted into aspartic acids. Among the 79 potential N-glycopeptides that were detected (S2
and S3 Tables), 13 N-glycopeptides were detected as deamidated peptides, even in the absence
of PNGase F-treatment (S3 Table), indicating that those 13 glycopeptides are formed by dea-
midation of the asparagine residues in a non-enzymatic fashion. The presence of N-glycans on
the remaining 66 peptides (S2 Table) was further confirmed by the detection of signals for N-
GlcNAc peptide ions on LC/MS/MS analysis of PNGase F-untreated sample [32]. Through this
analysis, 18 N-glycopeptides derived from 12 glycoproteins were unequivocally identified in the
Ngly1−/−;Engase−/− cytoplasm (Table 4, S1 Fig for product ion spectra). A comparison of the MS
peak areas of these glycopeptides between Ngly1−/−;Engase−/− and wild-type revealed that larger
signals were detected for several N-glycopeptides in the Ngly1−/−;Engase−/− cytoplasm samples
(Table 4, Fig 5B), while our analysis is by no means quantitative and the difference in the amount
of N-glycoproteins in the two different cells may also be due to the differential recovery of the
N-glycoproteins during the concentration of the N-glycoproteins. Nevertheless, our data clearly
indicates that, indeed, the cytoplasm did contain N-glycoproteins, which may become potential
substrates for Ngly1/ENGase in the cytoplasm and therefore can serve as precursors for N-
GlcNAc proteins.
Discussion
In this study, the functional significance of the Ngly1 gene in mice were characterized. The
results are consistent with the recent reports on NGLY1-deficient human subjects bearing muta-
tions in the NGLY1 allele [22–26]. Surprisingly, the lethality of the Ngly1−/− mice was partially
suppressed by the additional knockout of the Engase gene. This result is consistent with findings
reported in an earlier study [27], which showed that the disruption of ERAD in Ngly1-KO cells
was restored by the additional deletion of Engase, at an individual level. Through analyses of vari-
ous mutants for Ngly1 gene orthologues, an enzyme-independent function of the Ngly1-ortholo-
gue was proposed for some organisms [15, 18, 33]. The results reported herein clearly suggest,
however, that the embryonic lethal phenotype of Ngly1−/− mice is mainly related to its deglycosy-
lation-dependent function, given the fact that the lethality was partially suppressed by the addi-
tional deletion of Engase, a gene encoding another cytoplasmic deglycosylating enzyme.
Regarding the ventricular septum defect observed for Ngly1−/− embryos, it should be noted
that no significant heart problems have been reported for human patients [22–26], suggesting
that the functional importance of Ngly1 for the heart may be limited to its embryonic develop-
mental stage. In this connection, it is also noteworthy that one of the patients was diagnosed as
“small drop out in interventricular septum” by a fetal echo analysis (personal communication
from Mr. Andreas Thermann).
Fig 5. N-GlcNAc hypothesis and the accumulation of N-glycoproteins in the cytoplasm of Ngly1−/−;Engase−/− MEF cells. (A)
Schematic representation of an N-GlcNAc hypothesis and therapeutic treatment of NGLY1-deficiency based on ENGase inhibition. In the
absence of Ngly1, ENGase acts on some portions of unfolded glycoproteins to form N-GlcNAc proteins. The presence of an excess of N-
GlcNAc proteins somehow results in detrimental effects on cells/mice. (B) Relative peak area intensity (%) of glycopeptides observed in
Ngly1−/−;Engase−/− MEF cells. The peak area of each glycopeptide in wild-type MEF cells was identified as 100% and the relative ratio of
the glycopeptide peak area in Ngly1−/−;Engase−/− MEF cells were calculated. Shown are the average values for two samples that were
independently prepared.
https://doi.org/10.1371/journal.pgen.1006696.g005
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While the lethality of the Ngly1−/− mice was partially rescued by the additional deletion of
Engase or by changing the genetic background, recognizable phenotypes were still observed in
the Ngly1−/−;Engase−/− mice, as well as the Ngly1−/− mice in the C57BL/6 and ICR mixed back-
ground. It should be noted here that most of the phenotypes observed for those mice are remi-
niscent of the symptoms observed for an NGLY1-deficiency in human subjects (S4 Table).
Since the Ngly1−/− mice are embryonic lethal in the C57BL/6 background, the Ngly1−/−;
Engase−/− mice as well as the Ngly1−/− mice in the C57BL/6 and ICR mixed background could
serve as viable model animals for studying the functions of Ngly1, which could be of great
value, especially for evaluating the efficacy of potential drugs for the treatment of NGLY1-defi-
ciency subjects in the future.
With respect to the potential mechanism responsible for the detrimental effect of ENGase
in Ngly1−/− mice, we previously proposed an N-GlcNAc hypothesis as described above [27].
Such N-GlcNAc proteins were recently reported to be present in murine synaptosome proteins
[34]. In addition, in plants, at least one of the N-GlcNAc proteins was shown to be generated
by the action of the cytoplasmic ENGase [35]. There was also a report suggesting that the prox-
imal N-GlcNAc on N-glycosylation sites has a critical role in stabilizing carrier proteins [36].
We therefore hypothesize that ENGase might cleave glycans on misfolded glycoproteins in the
cytoplasm to generate N-GlcNAc proteins, and that the presence of an excess of these N-
GlcNAc proteins somehow contributes to the detrimental effects in mice, such as N-GlcNAc
proteins forming aggregates, or impairment of cytoplasmic O-GlcNAc signaling (N-GlcNAc
hypothesis) (Fig 5A). Indeed, we found that a model ERAD substrate was converted into an N-
GlcNAc-modified protein in Ngly1−/− MEF cells [27]. In this connection, it should be noted
that a GalNAc-GalNAc (GalNAc: N-acetylgalactosamine) interaction was recently reported to
occur in the binding of mucins with Tn (GalNAc α1-Ser/Thr) or sialyl Tn cancer antigens
Table 4. Detected N-glycopeptides in the cytoplasm of Ngly1−/−;Engase−/− MEF cells.
Protein name # Peptides sequences*
Acid ceramidase 1 SVLE N TTSYEEAK
Cathepsin D 2 YYHGELSYL N VTR
Fibronectin 3 N YTDCTSEGR
4 HEEGHML N CTCFGQGR
5 LDAPTNLQFV N ETDR
Fibulin-2 6 EGETCGAED N DTCGVSLYK
7 DLDECALGTH N CSEAETCHNIQGSFR
Follistatin-related protein 1 8 GS N YSEILDK
Hypoxia up-regulated protein 1 9 VFGSQ N LTTVK
Lysosomal alpha-glucosidase 10 QVVE N MTR
Lysosomal-associated membrane glycoprotein 2 11 VQPF N VTK
N-acetylglucosamine-6-sulfatase 12 GPGIKP N QTSK
13 TPMT N SSIR
Peptidyl-prolyl cis-trans isomerase FKBP10 14 TLSRPPENC N ETSK
15 YHY N GTFEDGK
Prosaposin 16 T N SSFIQGFVDHVK
17 D N ATQEEILHYLEK
Thrombospondin-1 18 VV N STTGPGEHLR
*N in the peptide sequences indicates N-glycosylation site.
https://doi.org/10.1371/journal.pgen.1006696.t004
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[37]. It would be interesting to see if similar interactions, at least in part, contribute to the
aggregation of N-GlcNAc proteins. On the other hand, we have not been able to detect Ngly1-
deficient specific change in the O-GlcNAc modification among MEF cells by western blotting
(S2 Fig). However, the possibility that changes in specific O-GlcNAc proteins had occurred
cannot be excluded. Clearly, a more comprehensive analysis will be required. Moreover,
Ngly1-deficient specific protein aggregation was not observed by histological analyses (e.g.
Congo red staining, PAS staining) of tissue sections from mice embryos. Further studies will
be needed to verify our N-GlcNAc hypothesis and efforts are currently underway to identify
endogenous N-GlcNAc proteins in MEF cells derived from various genotypes (wild-type,
Ngly1−/−, Engase−/− and Ngly1−/−;Engase−/−). It should be noted that Ngly1-KO does not lead to
a general ERAD-defect [8, 9, 38]. These observations strongly indicate that the pathogenesis of
Ngly1−/− mice cannot be attributed to general ER stress, but rather specific substrates likely
appear to be involved.
We previously reported that larger amounts of N-glycoproteins appeared to be accumulated
in the cytoplasm of Ngly1−/−;Engase−/− MEF cells compared with those of wild-type, Ngly1−/−
or Engase−/− MEF cells [27]. To extend our analysis, in this study we identified several N-glyco-
proteins that had accumulated in the cytoplasm of Ngly1−/−;Engase−/− cells. Such glycoproteins
can serve as precursors for endogenous N-GlcNAc proteins that are potentially formed in
Ngly1−/− cells. While we used sequential detergent extraction for the cytoplasmic fraction to
minimize contamination of other organelles, traces of lysosomal components could still be
detected in the cytoplasmic fraction (S3 Fig). It is therefore possible that some glycoproteins of
lysosomal origin may be present due to contamination by lysosomes in the cytoplasmic
fraction.
In any event, the phenotypes observed for Ngly1−/− and Ngly1−/−;Engase−/− mice were
found to be very analogous to the symptoms observed in patients with an NGLY1-deficiency
(S4 Table), which make those mice valuable animal models for this genetic disorder. It should
also be noted that the degree of suppression by Egnase-deletion are distinct among phenotypes
(ex Fig 2). These observations clearly suggest that multiple pathways, i.e. ENGase-dependent
and–independent pathways, are involved in the pathogenesis of Ngly1-KO mice or NGLY1-
deficiency subjects.
Since many of the Ngly1−/−;Engase−/− mice in both the C57BL/6 background and the
C57BL/6 and ICR mixed background survive for more than 1 year after birth (one lived for
more than 2 years), this either suggests that (1) once they escape the developmental defect dur-
ing embryogenesis, the Ngly1−/− mice could have a relatively normal life span or (2) the effect
of suppression by Engase-deletion is quite effective for adult mice. However, the Ngly1−/− mice
in the C57BL/6 and ICR mixed background showed quite severe phenotypes, favoring the lat-
ter possibility. Moreover, the additional deletion of Engase in the C57BL/6 and ICR back-
ground also resulted in a significant improvement of the phenotypes (% survival, body weight
gain), further supporting the conclusion that a defect in the Engase-gene has strong positive
effects for viable mice. In this connection, it should be noted that, while the birth rate of
Ngly1−/−;Engase−/− mice from Ngly1−/+;Engase−/− cross was found to be better in the C57BL/6
and ICR mixed background (12.33%) than the C57BL/6 homogeneous background (8.98%)
(Tables 2 and 3), it was still significantly lower than the expected rate (25%). These results
clearly suggest that the deletion of Engase is not sufficient to fully suppress the Ngly1 defect
during embryogenesis. Further studies will be required to understand the molecular details on
the functional importance of Ngly1 in embryogenesis.
Given the dramatic rescue of the mice phenotypes by the additional Engase deletion, one
could easily envision that an in vivo inhibitor of cytoplasmic ENGase would be a promising
therapeutic approach for the treatment of an NGLY1-deficiency in humans (Fig 5A). It has
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previously been shown that the thiazoline modified oligosaccharide functions as an effective
inhibitor for the cytoplasmic ENGase [39], and it may be possible to design cell permeable
inhibitors for ENGase derived from this compound.
Materials and methods
Ethics statement
All animal experiments were approved by the institutional committee of RIKEN (approved
number is: H28-2-003(2)). All mice in this study were euthanized by cervical dislocation.
Mice
We generated Ngly1- or Engase-deficient mice as described previously [27]. Mice were housed
in a facility with access to food and water and were maintained under 12-hour light/12-hour
dark cycle.
Engase−/− mice analyses
Engase−/− mice analyses were performed at Japan Mouse Clinic (http://ja.brc.riken.jp/lab/jmc/
mouse_clinic/en/index.html). For open field test, 18 Engase+/+ mice, 21 Engase−/+ mice and 20
Engase−/− mice were used. For RIKEN modified-SHIRPA, hematology, urinalysis, clinical
blood chemistry, pathology, blood pressure, and electrocardiogram tests, 11 Engase+/+ mice,
14 Engase−/+ mice and 14 Engase−/− mice were used. For light/dark transition, home-cage
activity, tail suspension, hot plate, and tail flick tests, 7 Engase+/+ mice, 7 Engase−/+ mice and 6
Engase−/− mice were used.
Cell cultures
MEF cells were isolated from E13.5 or E14.5 embryos by trypsinization [40]. The isolated MEF
cells were cultivated in DMEM (4.5 g/L glucose, 10% FBS, 100 unit/mL penicillin and 100 μg/
mL streptomycin) at 37˚C in a 5% CO2 atmosphere.
Genotyping
Genotyping to confirm the targeted disruption of Ngly1 and ENGase was performed by PCR
analysis using genomic DNA extracted from the tail or amnion and 8 sets of primers, as shown
in S1 Table. PCR products were separated by 2(w/v)% agarose gel electrophoresis, and the
band size was analyzed. Primer set 1–2, 3–4, 5–6, 7–8 can detect Ngly1+/+, Ngly1−/−, Engase+/+,
Engase−/− allele respectively. PCR product size (band size) of each primer sets are shown in S1
Table.
Histology
Embryos were fixed in Bouin’s solution. Fixed embryos were washed with 70% ethanol until
the yellow color of picric acid was no longer visible. The washed embryos were dehydrated
through a series of ethanol solutions (70%, 80%, 90%, 95%, 99% and 100%), cleared with
xylene, and embedded in paraffin. Samples were sectioned at 5 μm and stained with hematoxy-
lin and eosin (HE staining) using the general protocol.
Micro-CT analysis
The collected embryos were fixed with a 10% neutral buffered formalin solution (SIGMA).
Fixed embryos were soaked in contrast agent, a 1:3 mixture of Lugol solution and deionized
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distilled water and then analyzed by μ-CT. μ-CT analyses were performed as previously
reported [41]. Briefly, mouse embryos were scanned using a SCANXMATE-E090 scanner
(Comscantechno) at a tube voltage peak of 40 kVp and a tube current of 100 μA. Samples were
rotated 360˚ in steps of 0.24˚, generating 1500 projection images. The μ-CT data were recon-
structed at an isotropic resolution of 10.5 μm. Three-dimentional, tomographic images were
obtained using the OsiriX software (www.osirix-viewer.com).
Purification of (His)6-tagged N-terminal mouse Ngly1 (1–181) and raising
an antibody against Ngly1
An anti-mouse Ngly1 antibody was raised against the E. coli expressed N-terminus fragment
of Ngly1 using pET-mPng1N [42], which express the (His)6-tagged N-terminal fragment of
Ngly1 (aa1-181). In brief, to a 500 mL BL21(DE3)pLysS suspension of growing-phase cells car-
rying pET-mPng1N, was added isopropyl-β-thiogalactoside (final conc. 1 mM) at 37˚C for 3
hours. The cells were then collected, suspended in 25 mL of lysis buffer (50 mM Tris-HCl
buffer, pH 8.0, with 1 mM Pefabloc (Roche) and 0.15 M NaCl) with 200 μg/mL lysosyme and
incubated on ice for 30 min. Cells were lysed by sonication, and a crude cell extract was
obtained by removing the debris. A 12 ml portion of the protein extract (equivalent to 240 ml
E. coli culture) was applied to a Profinia protein purification system with a Bio-Scale Mini Ni-
IMAC Profinity column (Bio-Rad) according to the manufacturer’s protocol. The purified
(His)6-tagged protein thus obtained (2.5 mL) was desalted by passage through a PD-10 column
(GE), and the purified protein fraction thus obtained (~4 mg/mL) was used as an immunogen.
The antiserum raised against the purified Ngly1 (aa1-181), as well as the affinity purified IgG
fraction using the antigen-conjugated resin, was prepared by Biogate Co., Ltd (Gifu, Japan).
Preparation of cytoplasmic fraction from MEF cells
Cultured MEF cells were washed with PBS 3 times. The following steps were carried out either
on ice or at 4˚C. Cells collected were suspended with 10 mM Tris-HCl buffer (pH7.5) contain-
ing 1mM ethylenediaminetetraacetic acid (EDTA), 250 mM sucrose, 1 mM dithiothreitol
(DTT), 1 mM AEBSF (Pefabloc SC, Roche) and various protease inhibitors (1 × complete pro-
tease inhibitor cocktail (Roche)) at a density of 5 × 107 cell/mL, and were homogenized using a
Potter-Elvehjem homogenizer. The extracts thus obtained were cleared at 15,000 rpm for 10
min at 4˚C and the supernatant was transferred to a new tube. The sample was ultracentri-
fuged at 100,000×g for 1 h at 4˚C, and the supernatant was collected and used as the cyto-
plasmic fraction.
Subcellular fractionation through sequential detergent extraction
2 × 106 MEF cells were seeded on a 150 cm2 flask 48 h before extraction. Cultured MEF cells
were washed 3 times with 10 mL of PBS. The flask was gently coated with 1 mL of permeabili-
zation buffer (25 mM Hepes (pH 7.2), 110 mM potassium acetate, 2.5 mM magnesium acetate,
1 mM ethyleneglycoltetraacetic acid (EGTA), 1 mM DTT, 1 mM phenylmethylsulfonyl fluo-
ride (PMSF), 0.015(wt/vol)%, digitonin) and slowly rocked at 4˚C for 5 min. The buffer was
collected and centrifuged at 7,500×g for 10 min at 4˚C. The supernatant was transferred to a
new tube and used as cytoplasmic fraction for glycoproteomics analyses. The flask was then
washed with 5 mL of wash buffer (25 mM Hepes (pH 7.2), 110 mM potassium acetate, 2.5 mM
magnesium acetate, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 0.004(wt/vol)%, digitonin). The
flask was coated 1 mL of lysis buffer (25 mM Hepes (pH 7.2), 400 mM potassium acetate, 15
mM magnesium acetate, 1 mM DTT, 1 mM PMSF, 1(wt/vol)% NP-40, 0.5(wt/vol)% sodium
deoxycholate) and rocked at 4 for 5 min. The buffer was collected and centrifuged at 7,500×g
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for 10 min at 4˚C. The supernatant was transferred to a new tube and used as membrane
fraction.
Sample preparation for glycoproteomics analysis
The sample preparation were performed as previously described [32]. Briefly, following the
addition of 4 μL of 1 M DTT, the detergent extracted cytoplasmic fractions (100 μL, 60 μg)
were incubated at 65˚C for 30 min. 5.6 μL of 1 M iodoacetoamide was added and the mixtures
were incubated at room temperature for 40 min in the dark. The reaction was stopped by add-
ing 2.4 μL of 1 M DTT, and then desalted by acetone precipitation prior to tryptic digestion.
The precipitated samples were dissolved in 30 μL of 50 mM Tris-HCl (pH 8.5) containing 0.1
(w/v)% sodium deoxycholate. Modified trypsin (3 μg) (Promega) was added to the samples,
and the mixtures were incubated at 37˚C for 16 h. The peptide mixtures were diluted with
Milli-Q water to a final volume of 50 μL. A five-fold volume of ice cold acetone was then
added to the peptides and the glycopeptide mixtures were incubated at −25˚C for at least 16 h
to precipitate the glycopeptides (glycopeptides enrichment). The precipitated glycopeptide
fractions were collected by centrifugation at 12,000×g for 10 min at 20˚C, and the precipitated
glycopeptides fractions were dissolved in Milli-Q water. A part of the glycopeptides fractions
were desalted using a Pierce C-18 Spin Column (Thermo Scientific) following the manufactur-
er’s instructions and used for glycopeptide analyses. A second portion of the glycopeptide frac-
tion was dissolved in 50 μL of 50 mM phosphate buffer (pH 7.2) containing 10 mM EDTA and
used for analyses of deaminated peptides. To release the N-glycans, the sample was incubated
with 1 U of PNGase F with 50% glycerol at 37˚C overnight. After drying with a SpeedVac con-
centrator, the sample was desalted as described above. PNGase F treated samples were used for
analyses of deamidated peptides to estimate the N-glycosylation sites on peptides.
Liquid chromatography/mass spectrometry (LC/MS) analyses
The samples prepared were dissolved in 20 μL of 0.1% formic acid, and a 1 μL aliquot of the
sample was injected into an EASY-nLC 1000 (Thermo Scientific) with an Acclaim PepMap
100 trapping column (75 μm×2 cm, nanoViper; Thermo Scientific) and a Nano HPLC Capil-
lary Column (75 μm×120 mm, 3 μm, C18; Nikkyo Technos). The mobile phases were 0.1% for-
mic acid (A buffer) and 0.1% formic acid in acetonitrile (B buffer). The glycopeptides were
eluted at a flow rate of 0.3 μL/min with a linear gradient from 0 to 45% B over 55 min. Mass
spectra were acquired on a Q Exactive mass spectrometer (Thermo Scientific) equipped with
Nanospray Flex Ion Source (Thermo Scientific). The electrospray voltage was 2.0 kV, and the
resolution was 70,000. Full mass scans were performed at a range of m/z 700–2,000, and prod-
uct ion spectra were acquired data-dependently in the positive ion mode. The deglycosylated
peptides were analyzed in a similar manner with the exception of full mass scans at m/z 350–
2000.
Identification of glycopeptides
The deglycosylated (PNGase F treated) peptides were identified by a database search analysis
using the SEQUEST search engine (Thermo Scientific) with applying the following parame-
ters: a specified trypsin enzymatic cleavage with 2 possible missed cleavages, precursor mass
tolerance of 6 ppm, fragment mass tolerance of 0.02 Da, static modification of cysteine (carba-
midomethylation), and dynamic modification of methionine (oxidation) and asparagine (dea-
midation). All of the identified peptides were then filtered at a false discovery rate (FDR)
threshold of 1%. The amino acid sequences of glycopeptides were identified by matching
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between the product ion of peptide carrying a single N-acetylglucosamine residue and the
identified deglycosylated peptide.
Western blotting
Cytoplasmic fractions of MEF cells derived from Ngly1−/−, or wild type mice were separated by
sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and electroblotted
onto polyvinylidene fluoride (PVDF) membrane. The membrane was blocked for 1 h with 4
(w/v)% skim milk in PBS and incubated with anti-mouse Ngly1 antibody in PBS supple-
mented with 0.05% (wt/vol) Tween20 (PBST) (1:3000) at 4˚C for 16 h, followed by HRP goat
anti-rabbit IgG (1:3000, GE Healthcare) in PBST at room temperature for 2 h. The membranes
were monitored by an Immobilon Western Chemiluminescent HRP Substrate (Millipore).
The chemiluminescence was visualized using a LAS-3000 Imager (Fujifilm).
Preparation of cytoplasm from mice tissues
Livers obtained from 7-week-old female mice of ICR background (n = 3), and C57BL/6 back-
ground (n = 3), as well as a 16-week-old female C57BL/6 mouse of Engase−/− (n = 1) were sus-
pended in 2 volumes of cytoplasm extraction buffer containing 10 mM Hepes-NaOH (pH7.4),
250 mM sucrose, 1 mM DTT, 1 mM ethylenediaminetetraacetic acid (EDTA), 1×complete
protease inhibitior cocktail (EDTA-free; Roche) and 1 mM Pefabloc (Roche), and homoge-
nized on ice using a Potter-Elvehjem homogenizer. The homogenate was centrifuged twice at
10,000xg for 5 min at 4˚C to remove debris, and then further centrifuged at 100,000xg for 60
min at 4˚C. The supernatant was collected, not including the floating lipid layer, as the cyto-
solic extract for the ENGase activity assay. The amount of protein was determined using a
Bradford assay (Bio-Rad Protein Assay, Bio-Rad) with bovine serum albumin as the standard.
ENGase assay
The ENGase activity assay reaction (total 10 μL) included 2 μL of cytosolic fraction in which
the protein concentration was adjusted to 30 mg/mL), 4 pmol of Man9GlcNAc2-PA (TaKaRa
Bio Inc.) in a final 50 mM of Mes-NaOH buffer (pH6.0), and the reaction was carried at 30˚C
for 1 hour. The reaction was terminated by adding 100 μL 75% (vol/vol) ethanol and the result-
ing solution was incubated on ice for 15 min. After centrifugation at 15,000×g for 10 min at
4˚C, the supernatant was evaporated to dryness and dissolved in 40 μL of water, and was sub-
jected to HPLC analysis using a Shodex NH2P-50 4E column as described previously [43].
Supporting information
S1 Fig. Product ion spectra of glycopeptides listed in Table 4. (A-R) Product ion spectruca
of glycopeptides derived from Acid ceramidase (A), Cathepsin D (B), Fibronectin (C-E), Febu-
lin-2 (F, G),Follistatin-related protein 1 (H), Hypoxia up-regulated protein 1 (I), Lysosomal
alpha-glucosidase (J), Lysosomal-associated membrane glycoprotein 2 (K), N-acetylglucosa-
mine-6-sulfatase (L, M), Peptidyl-prolyl cis-trans isomerase FKBP10 (N, O), Prosaposin (P,
Q), and Thrombospondin-1 (R). Square: N-acetylhexosamine, circle: hexose, triangle: deoxy-
hexose.
(TIF)
S2 Fig. O-GlcNAc modification is not different among Ngly1+/+, Ngly1−/−, Ngly1−/−;
Engase−/−,MEF cells. (A, B) Cell lysates form MEF cells were subjected to western blotting
using anti-O-GlcNAc antibody (CTD110.6, Biolegend). Left and right panels show the result
of western blotting and amido black staining of the same membrane, respectively. In panel B,
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membrane was treated with 50 mM NaOH at 45˚C for 19 h (β-elimination) to remove the O-
GlcNAc modification. Representative data were shown (n = 3).
(TIF)
S3 Fig. Confirmation of cell fractionation using subsequent detergent extraction. Extracted
cytoplasmic fraction and membrane fraction were subjected to western blotting using anti-
LAMP1 (Abcam, ab24170) (A), anti-PDI (Cell Signaling Technology, #2446S), and anti-
GAPDH (Millipore, MAB374). Representable data were shown (n = 3).
(TIF)
S1 Movie. Behavioral observations of Ngly1+/+;Engase−/− mice (8 months of age).
(MP4)
S2 Movie. Behavioral observations of Ngly1−/−;Engase−/− mice (8 months of age). This
mouse is a littermate of the mouse shown in S1 Movie. This mouse showed trembling, a bent
spine and coarse fur.
(MP4)
S3 Movie. Behavioral observations of Ngly1+/+;Engase−/− mice (left) and Ngly1−/−;Engase−/−
mice (right). They are littermates and 8 months of age. Ngly1−/−;Engase−/− mice showing
hind-limb clasping and front-limb shaking.
(MP4)
S1 Table. Sequence of primers used in this study. Each primer set number corresponds to
the number in Fig 1B and 1C.
(DOCX)
S2 Table. List of peptides detected as the potential N-glycopeptides after PNGase F-diges-
tion. N in the peptide sequence indicates the potential N-glycosylation sites.
(DOCX)
S3 Table. List of peptides detected as deamidated peptides in both PNGase F-treated and
-untreated samples. n in the peptide sequence indicates the sites most likely deamidated in a
PNGase F digestion-independent manner.
(DOCX)
S4 Table. Comparison of phenotypes of Ngly1−/−;Engase−/− mice in C57BL/6 background
or Ngly1−/− mice in C57BL/6 and ICR mixed background with symptoms of NGLY1-defi-
ciency subjects. Description of symptoms is according to ref. 24.
(DOCX)
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